SVE
ENG
Stockholm, October 24, 2012 – InDex Pharmaceuticals today announced that it has been granted a Japanese patent by the Japan Patent Office (JPO). The patent provides protection for the use of…
– Novel patent for Phase III lead drug candidate filed in the EU, US – Stockholm, August 30, 2012 – InDex Pharmaceuticals today announced the filing of a new patent with the United States Patent…
– InDex Pharmaceuticals reports positive clinical data in peer-reviewed journal Inflammatory Bowel Diseases – Stockholm, June 19, 2012 – InDex Pharmaceuticals today announced the publication of…
Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network Stockholm, May 29, 2012 – InDex Pharmaceuticals today announced that Stig Løkke Pedersen…
Stockholm, April 26, 2012 – InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO). The patent provides additional…
InDex Pharmaceuticals Names Pernilla Sandwall Head of Clinical Operations and Thomas Knittel Chief Medical Officer Stockholm, April 11, 2012 – InDex Pharmaceuticals today announced two additions…
Personalized treatment option for patients with refractory ulcerative colitis Stockholm, March 20, 2012 – InDex Pharmaceuticals today announced the development of a companion diagnostic test for…
TLR9 Agonist for the Treatment of Chronic, Active, Treatment-Refractory Ulcerative Colitis Stockholm, March 6, 2012 – InDex Pharmaceuticals today announced the start of the COLLECT trial, a European…
